Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6179)
All Articles published online
|
Publishing Process of This Article
|
Jan 26, 2023 (publication date) through Feb 7, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Wang YW, Wang XH, Wang HX, Yu RH. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience. World J Clin Cases 2023; 11(3): 566-575 [PMID: 36793628 DOI: 10.12998/wjcc.v11.i3.566] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Wang YW, Wang XH, Wang HX, Yu RH. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience. World J Clin Cases 2023; 11(3): 566-575 [PMID: 36793628 DOI: 10.12998/wjcc.v11.i3.566] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v11/i3/566.htm |
| Number | Citing Articles |
| 1 |
Yang Yang, Yuxin Zhang, Ran Zhang, Manna Li, Hongping Wan, Wenjun Yan, Kaiping Luo, Qipeng Huang, Daijin Ren, Gaosi Xu. Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage. European Journal of Pharmacology 2025; 1000: 177739 doi: 10.1016/j.ejphar.2025.177739
|
| 2 |
Jiadan Ye, Chunyan Zhang, Xiaolei Ren, Lin Huang, Xiaohong Zhang. Efficacy and safety of rituximab in Chinese patients of glomerular kidney diseases: An observational study. Medicine 2025; 104(37): e44127 doi: 10.1097/MD.0000000000044127
|
| 3 |
Khuram Bashir, Muhammad Rashid Asghar, Nayyar Saleem, Muhammad Shahzil, Aimon Riaz, Muhammad Nauman Hashmi, Ahmed Sheraz. Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective study. Brazilian Journal of Nephrology 2026; 48(2) doi: 10.1590/2175-8239-jbn-2025-0228en
|
| 4 |
L.D. Denova, I.V. Krasiuk. A clinical case of primary membranous glomerulonephritis with nephrotic syndrome and resistance to standard treatment. KIDNEYS 2023; 12(4): 211 doi: 10.22141/2307-1257.12.4.2023.431
|
| 5 |
Yang Yang, Kaiqi Cheng, Gaosi Xu. Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelines. European Journal of Pharmacology 2024; 982: 176928 doi: 10.1016/j.ejphar.2024.176928
|
| 6 |
Khuram Bashir, Muhammad Rashid Asghar, Nayyar Saleem, Muhammad Shahzil, Aimon Riaz, Muhammad Nauman Hashmi, Ahmed Sheraz. Redução dos níveis do anticorpo anti-PLA2R como preditor de resposta ao tratamento na nefropatia membranosa primária: um estudo retrospectivo. Brazilian Journal of Nephrology 2026; 48(2) doi: 10.1590/2175-8239-jbn-2025-0228pt
|
| 7 |
Muhammad Umar Ahsan, Arooj Tabassum, Kinza Naseem, Imran Bin Zahid. Obinutuzumab: a new frontier in the treatment of refractory idiopathic membranous nephropathy. International Urology and Nephrology 2025; 57(9): 3075 doi: 10.1007/s11255-025-04500-7
|